Launched in Cambridge, Massachusetts, LUCA Biologics focuses primarily on treating women’s health. The company is currently focusing primarily on the female urinary tract infections (UTI).
The co-founder of LUCA, Jacques Ravel, who is a researcher in the Weizmann Institute of Science commented that there is an urgent need for innovation in the women’s health care system. “While our research started with metagenomic sequencing to generate large comparative data sets, we can now translate our findings into safe and effective treatments for widespread conditions that stigmatize and devastate millions of women each year,” she added.
The company started 15 years ago, primarily providing services in strain bank and gene catalog. Reports suggest LUCA has built a metagenomic and metatranscriptomic platform which will further identify and validate microbial strains that will help in modulating urogenital and vaginal microbiome. Furthermore, LUCA also specializes in developing therapies for UTI, which are helpful in preterm birth (PTB) and bacterial vaginosis (BV).
The healthcare reports suggest microbiome which live in the human body are forming a crucial part in the field of therapeutics, and not only in the field of gastrointestinal diseases but also for treatment of central nervous system and psychiatric disorders.
The LUCA Biologics is credited for including microbiome in treating urinary tract infections and bacterial vaginosis. The research carried out by Javel especially indicated that vaginal bacteria was linked with “host response” associated with fertility or the time of birth.
Ravel also underlined the fact that women prone to high levels of specific type of bacteria underwent lesser risk for premature birth, whereas women with low levels of the same bacteria had high risks or premature births.
The study was published in Nature Communications.